Expression of calretinin by breast carcinoma and the potential for misdiagnosis of mesothelioma

Histopathology

Volumn 59, Issue 5, 2011, Pages 950-956

  Powell, George ^a   Roche, Heather ^b   Roche, William R ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Basal like; Breast cancer; Calretinin

Indexed keywords

CALRETININ; ESTROGEN RECEPTOR;

ARTICLE; BASAL CELL CARCINOMA; BREAST CARCINOMA; CANCER GRADING; DIAGNOSTIC ERROR; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; PLEURA BIOPSY; PLEURA METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; BREAST NEOPLASMS; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; NEOPLASM GRADING; TUMOR MARKERS, BIOLOGICAL;

EID: 81555200674     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04031.x     Document Type: Article

References (45)

1. Pokieser W, Cassik P, Fischer G, Vesely M, Ulrich W, Peters-Engl C. Malignant pleural and pericardial effusion in invasive breast cancer: impact of the site of the primary tumor. Breast Cancer Res. Treat. 2004; 83; 139-142.
2. Cancer Research UK. Accessed February 17 2009.
3. United Kingdom Health and Safety Executive. Accessed February 17 2009.
4. McCaughey WTE, Colby TV, Battifora H et al. Diagnosis of diffuse malignant mesothelioma: experience of a US/Canadian mesothelioma panel. Mod. Pathol. 1991; 4; 342-352.
5. Marchevsky AM. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch. Pathol. Lab. Med. 2008; 132; 397-491.
6. King JE, Hasleton PS. Immunohistochemistry and the diagnosis of malignant mesothelioma. Histopathology 2001; 38; 471-476.
7. Carella R, Deleonardi G, D'Errico A et al. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Am. J. Surg. Pathol. 2001; 25; 43-50.
8. Perou CM, Sorlie T, Elsen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406; 747-752.
9. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 2001; 98; 10869-10874.
10. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 2003; 100; 8418-8423.
11. Abd El-Rehim DM, Ball G, Pinder SE et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int. J. Cancer 2005; 116; 340-350.
12. Fulford LG, Reis-Filho JS, Ryder K et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res. 2007; 9; R4.
13. Luck AA, Evans AJ, Green AR, Rakha EA, Paish C, Ellis IO. The influence of basal phenotype on the metastatic pattern of breast cancer. Clin. Oncol. (R. Coll. Radiol.) 2008; 20; 40-45.
14. Abd El-Rehim DM, Pinder SE, Paish CE et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J. Pathol. 2004; 203; 661-671.
15. Rakha EA, Putti TC, Abd El-Rehim DM et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J. Pathol. 2006; 208; 495-506.
16. Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 2005; 11; 5678-5685.
17. Banerjee S, Reis-Filho JS, Ashley S et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J. Clin. Pathol. 2006; 59; 729-735.
18. Carey LA, Dees EC, Sawyer L et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 2007; 13; 2329-2334.
19. Neilson TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004; 10; 5367-5374.
20. Livasy CA, Karaca G, Nanda R et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod. Pathol. 2006; 19; 264-271.
21. Ordonez NG. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod. Pathol. 1998; 11; 929-933.
22. Lugli A, Forster Y, Haas P et al. Calretinin expression in human normal and neoplastic tissues: a tissue microarray analysis on 5233 tissue samples. Hum. Pathol. 2003; 34; 994-1000.
23. Fulford LG, Easton DF, Reis-Filho JS et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of the breast. Histopathology 2006; 49; 22-34.
24. NHS Cancer Screening Programmes and The Royal College of Pathologists, Pathology reporting of breast disease, NHSBSP Publication no. 58; 2005. Available from:.
25. Porter GJR, Evans AJ, Pinder SE et al. Patterns of metastatic breast carcinoma: influence of tumour histological grade. Clin. Radiol. 2004; 59; 1094-1098.
26. Office for National Statistics. Breast cancer survival, England and Wales, 1991-2003. Accessed February 17 2009.
27. Borasio P, Berruti A, Billé A et al. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients. Eur. J. Cardiothorac. Surg. 2008; 33; 307-313.
28. Bielsa S, Salud A, Martinez M et al. Prognostic significance of pleural fluid data in patients with malignant effusion. Eur. J. Intern. Med. 2008; 19; 334-339.
29. Doglioni C, Dei Tos AP, Laurino L et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am. J. Surg. Pathol. 1996; 20; 1037-1046.
30. Leers MPG, Aarts MMJ, Theunissen PHMH. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology 1998; 32; 209-216.
31. Cury PM, Butcher DN, Fisher C, Corrin B, Nicholson AG. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod. Pathol. 2000; 13; 107-112.
32. Comin CE, Novelli L, Boddi V, Paglierani M, Dini S. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum. Pathol. 2001; 32; 529-536.
33. Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J. Clin. Pathol. 2002; 55; 662-668.
34. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am. J. Surg. Pathol. 2003; 27; 1031-1051.
35. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Hum. Pathol. 2004; 35; 697-710.
36. Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod. Pathol. 2005; 18; 105-110.
37. Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A, Inai K. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Pathol. Int. 2007; 57; 190-199.
38. Mimura T, Ito A, Sakuma T et al. Novel marker D2-40, combined with calretinin, CEA, and TTF-1. Cancer 2007; 109; 933-938.
39. Miettenen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types. Am. J. Surg. Pathol. 2003; 27; 150-158.
40. Chu PG, Weiss LM. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod. Pathol. 2002; 15; 6-10.
41. Ordonez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod. Pathol. 2006; 19; 34-48.
42. Cathro HP, Stoler MH. The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors. Hum. Pathol. 2005; 36; 195-201.
43. Addis B, Roche H. Problems in mesothelioma diagnosis. Histopathology 2009; 54; 55-68.
44. Ordonez NG. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am. J. Surg. Pathol. 1998; 22; 1215-1221.
45. van deRijn M, Perou CM, Tibshirani R et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am. J. Pathol. 2002; 161; 1991-1996.